Immunogenic compositions for induction of anti-tumor immunity

Details Immunogenic compositions for induction of anti-tumor immunity Immunogenic compositions for induction of anti-tumor immunity

2008-05-27

2008-05-27

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S138100, C424S141100, C424S154100

Reexamination Certificate

active

07378092

ABSTRACT:
The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of:(i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and(ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition.Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

REFERENCES:
patent: 5874209 (1999-02-01), Karin et al.
patent: 0 438 312 (1991-07-01), None
patent: WO 92/13970 (1992-08-01), None
patent: WO 93/18792 (1993-09-01), None
patent: WO 96/01126 (1996-01-01), None
patent: WO 97/04092 (1997-02-01), None
patent: WO 98/18825 (1998-05-01), None
Gura (Science, v278, 1997, pp. 1041-1042).
Bellone et al. . (Immunology Today, v20 (10), 1999, pp. 457-462).
Gaiger et al. (Blood, vol. 96, No. 4, Aug. 2000, pp. 1480-1489).
Erez-Alon et al (Cancer Research, 1998, 58:5447-5452).
Jannot et al (BBRC, Jan. 1997, 230:242-246).
Erez-Alon et al, Cancer Research, 1998 58:5447-5452.
Cohen, I.R., “Natural Id-Anti-Id Networks and the Immunological Homunculus,” inTheories of Immune Networks(Allan et al., eds.), Springer-Verlag; Heidelberg, pp. 6-12 (1989).
Cohen, I.R., “The cognitive paradigm and the immunological homunculus,”Immunol Today, vol. 13, No. 12, pp. 490-494 (1992).
Cruse, J.M. et al.,Illustrated Dictionary of Immunology, CRC Press, p. 148 (1994).
el-Deiry, W.S. et al., “Definition of a consensus binding site for p53,”Nature Genet, vol. 1, No. 4, pp. 45-49 (1992).
Erez-Alon, N. et al., “Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: generation of sequence-specific anti-DNA antibodies and protection from tumor metastases,”Cancer Res, vol. 58, pp. 5447-5452 (1998).
Foord, O.S. et al., “A DNA binding domain is contained in the C-terminus of wild type p53 protein,”Nucleic Acids Res, vol. 19, pp. 5191-5198 (1991).
Gannon, J.V. et al., “Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form,”Embo J, vol. 9, No. 5, pp. 1595-1602 (1990).
Harlow, E. et al., “Monoclonal antibodies specific for simian virus 40 tumor antigens,”J Virol, vol. 39, pp. 861-869 (1981).
Hollstein, M. et al., “p53 mutations In human cancers,”Science, vol. 253, pp. 49-53 (1991).
Houbiers, J.G. et al., “In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53,”Eur J Immunol, vol. 23, pp. 2072-2077 (1993).
Jannot, C.B. et al., “Characterization of scFv-421, a Single-Chain Antibody Targeted to p53”,Biochem Biophys Res Comm, vol. 230, No. 2, pp. 242-246 (1997).
Lee, S. et al., “p53 and its 14Kda C-terminal domain recognize primary DNA damage in the form of insertion/deletion,”Cell, vol. 81, pp. 1013-1020 (1995).
Lubin, R. et al., “Analysis of p53 30 antibodies in patients with various cancers define B-cell epitopes of human p53) distribution on primary structure and exposure on protein surface”,Cancer Res, vol. 53, pp. 5872-5876 (1993).
Nicholson, A.G. et al., “Anti-tumor immune responses following monoclonal antibody therapy of ovarian cancer,”Proc Ann Meet Am Assoc Cancer Res, vol. 38 (XP002081861) (1997).
Nisonoff, A. et al., “Idiotypes: concepts and applications,”J Immunol, vol. 147, pp. 2429-2438 (1991).
Paul, W.E.,Fundamental Immunology, Raven Press, NY, Chapter 8, p. 242 (1993).
Ruiz, P.J. et al., “Idiotypic immunization induces immunity to mutated p53 and tumor rejection,”Nature Med, vol. 4, No. 6, pp. 710-712 (1998).
Schlichtholz, B. et al., “The immune response to p53) in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot,”Cancer Res, vol. 52, pp. 6380-6384 (1992).
Soussi T., “The humoral response to the tumor suppressor gene product p53) in human cancer. Implications for diagnosis and therapy,”Immunol Today, vol. 17. p. 354-356 (1996).
Stevenson, F.K. et al., “Idiotypic DNA vaccines against B-cell lymphoma,”Immunol Rev., vol. 145, pp. 211-228 (1995).
Tilkin A-F. et al., “Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer,”Eur J Immunol, vol. 25, pp. 1765-1769 (1995).
Wolkowicz, R. et al., “The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes,”Oncogene, vol. 10, pp. 1167-1174 (1995).
Yanuck, M. et al., “A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+cytotoxic T-cells,”Cancer Res, vol. 53, pp. 3257-3261 (1993).
Zusman, I. et al., “Tumor-Suppressor effects of anti-p53 IgG on chemical induced colon cancer in rats,”Cancer J, vol. 110, No. 2, pp. 116-120 (1997).

Affiliated with

Also associated with

Rating

Immunogenic compositions for induction of anti-tumor immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic compositions for induction of anti-tumor immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic compositions for induction of anti-tumor immunity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2792216